Pharmacological therapy for acute respiratory distress syndrome

Raksha Jain, Anthony DalNogare

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Acute respiratory distress syndrome (ARDS) is an inflammatory process caused by a variety of direct and indirect injuries to the lungs. Despite improvements in supportive care and advances in ventilator management, mortality in patients with ARDS remains high. Multiple pharmacological interventions have been investigated but have not shown improved survival. Clinical trials using corticosteroids, prostaglandins, nitric oxide, prostacyclin, surfactant, lisofylline, ketoconazole, N-acetylcysteine, and fish oil have been unable to show a statistically significant improvement in patient mortality. As more is understood about the pathophysiology of ARDS, treatment strategies statistically as increasing alveolar fluid clearance through activation of sodium channels, enhancing repair of alveolar epithelium with growth factors, inhibiting fibrin deposition, blocking proinflammatory transcription factors, preventing the effect of potent vasocontrictors such as endothelin, and using antibodies against key inflammatory cytokines are being explored. This review focuses on the pharmacological treatments studied clinically, proposed reasons for their lack of success, and new concepts emerging in ARDS therapy.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalMayo Clinic Proceedings
Volume81
Issue number2
StatePublished - 2006

Fingerprint

Adult Respiratory Distress Syndrome
Pharmacology
lisofylline
Ketoconazole
Mortality
Fish Oils
Sodium Channels
Endothelins
Acetylcysteine
Lung Injury
Epoprostenol
Mechanical Ventilators
Therapeutics
Fibrin
Surface-Active Agents
Prostaglandins
Intercellular Signaling Peptides and Proteins
Adrenal Cortex Hormones
Nitric Oxide
Transcription Factors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacological therapy for acute respiratory distress syndrome. / Jain, Raksha; DalNogare, Anthony.

In: Mayo Clinic Proceedings, Vol. 81, No. 2, 2006, p. 205-212.

Research output: Contribution to journalArticle

Jain, Raksha ; DalNogare, Anthony. / Pharmacological therapy for acute respiratory distress syndrome. In: Mayo Clinic Proceedings. 2006 ; Vol. 81, No. 2. pp. 205-212.
@article{2f1a2e71c1e042419e2f11284ebf5bdb,
title = "Pharmacological therapy for acute respiratory distress syndrome",
abstract = "Acute respiratory distress syndrome (ARDS) is an inflammatory process caused by a variety of direct and indirect injuries to the lungs. Despite improvements in supportive care and advances in ventilator management, mortality in patients with ARDS remains high. Multiple pharmacological interventions have been investigated but have not shown improved survival. Clinical trials using corticosteroids, prostaglandins, nitric oxide, prostacyclin, surfactant, lisofylline, ketoconazole, N-acetylcysteine, and fish oil have been unable to show a statistically significant improvement in patient mortality. As more is understood about the pathophysiology of ARDS, treatment strategies statistically as increasing alveolar fluid clearance through activation of sodium channels, enhancing repair of alveolar epithelium with growth factors, inhibiting fibrin deposition, blocking proinflammatory transcription factors, preventing the effect of potent vasocontrictors such as endothelin, and using antibodies against key inflammatory cytokines are being explored. This review focuses on the pharmacological treatments studied clinically, proposed reasons for their lack of success, and new concepts emerging in ARDS therapy.",
author = "Raksha Jain and Anthony DalNogare",
year = "2006",
language = "English (US)",
volume = "81",
pages = "205--212",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Pharmacological therapy for acute respiratory distress syndrome

AU - Jain, Raksha

AU - DalNogare, Anthony

PY - 2006

Y1 - 2006

N2 - Acute respiratory distress syndrome (ARDS) is an inflammatory process caused by a variety of direct and indirect injuries to the lungs. Despite improvements in supportive care and advances in ventilator management, mortality in patients with ARDS remains high. Multiple pharmacological interventions have been investigated but have not shown improved survival. Clinical trials using corticosteroids, prostaglandins, nitric oxide, prostacyclin, surfactant, lisofylline, ketoconazole, N-acetylcysteine, and fish oil have been unable to show a statistically significant improvement in patient mortality. As more is understood about the pathophysiology of ARDS, treatment strategies statistically as increasing alveolar fluid clearance through activation of sodium channels, enhancing repair of alveolar epithelium with growth factors, inhibiting fibrin deposition, blocking proinflammatory transcription factors, preventing the effect of potent vasocontrictors such as endothelin, and using antibodies against key inflammatory cytokines are being explored. This review focuses on the pharmacological treatments studied clinically, proposed reasons for their lack of success, and new concepts emerging in ARDS therapy.

AB - Acute respiratory distress syndrome (ARDS) is an inflammatory process caused by a variety of direct and indirect injuries to the lungs. Despite improvements in supportive care and advances in ventilator management, mortality in patients with ARDS remains high. Multiple pharmacological interventions have been investigated but have not shown improved survival. Clinical trials using corticosteroids, prostaglandins, nitric oxide, prostacyclin, surfactant, lisofylline, ketoconazole, N-acetylcysteine, and fish oil have been unable to show a statistically significant improvement in patient mortality. As more is understood about the pathophysiology of ARDS, treatment strategies statistically as increasing alveolar fluid clearance through activation of sodium channels, enhancing repair of alveolar epithelium with growth factors, inhibiting fibrin deposition, blocking proinflammatory transcription factors, preventing the effect of potent vasocontrictors such as endothelin, and using antibodies against key inflammatory cytokines are being explored. This review focuses on the pharmacological treatments studied clinically, proposed reasons for their lack of success, and new concepts emerging in ARDS therapy.

UR - http://www.scopus.com/inward/record.url?scp=32144459541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144459541&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 205

EP - 212

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -